🇺🇸 FDA
Pipeline program

Immune Globulin Intravenous (IGIV)

TAK-664-3001

Phase 3 mab completed

Quick answer

Immune Globulin Intravenous (IGIV) for Primary Immunodeficiency Diseases (PID) is a Phase 3 program (mab) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Primary Immunodeficiency Diseases (PID)
Phase
Phase 3
Modality
mab
Status
completed

Clinical trials